

ORA-Blend[®] SF

www.Padagis.com

Flavored Sugar-Free Oral Suspending Vehicle



ORA-Blend SF is a flavored sugar-free oral suspending vehicle used to simplify the process involved in the extemporaneous compounding of oral suspensions. Medicated powder can be incorporated into ORA-Blend SF to form elegant, uniform and physically stable suspensions.

Applications

ORA-Blend SF combines the suspending properties of ORA-Plus[®] with the flavoring agents of ORA-Sweet[®] SF and is ideal for:

- Pediatric suspensions
- Geriatric suspensions

Properties

ORA-Blend SF is an aqueous-based sweetened vehicle consisting of a synergistic blend of suspending agents that have a high degree of colloidal activity. The suspending agents form a structured, gel-like matrix which suspends particles and allow for little settling. ORA-Blend SF is buffered to a slightly acidic pH to help reduce degradation of medicinal agents through oxidation. An anti-foam agent is incorporated in ORA-Blend SF to allow for vigorous shaking with minimal foam.

Contains:

Purified water, sorbitol, glycerin, berry citrus flavor (contains FD&C Red #40), microcrystalline cellulose, carboxymethylcellulose sodium, xanthan gum, carrageenan, calcium sulfate, trisodium phosphate and sodium saccharin, sodium phosphate, citric acid and sodium citrate as buffers, dimethicone antifoam emulsion. Preserved with methylparaben, propylparaben and potassium sorbate.

Specifications

Appearance: Opaque, pinkish liquid

pH: Approximately 4.2

Taste: Sweet citrus-berry flavor

Viscosity: Approximately 1000 cps at 25°C via Brookfield viscometer

Osmolality: 1027 mOsm/kg

Available through your wholesaler or distributor.

Perrigo[®]

Compounding Examples



LAMOTRIGINE 1 mg/mL, 100 mL¹

| | |
|---------------------------|-------------|
| Lamotrigine 100 mg/tablet | 1 tablet |
| ORA-Blend SF | q.s. 100 mL |

- Expiration 91 days at 4°C and 25°C
- Protect from light
- Shake well before using

SPIRONOLACTONE 5 mg/mL, plus HYDROCHLOROTHIAZIDE 5 mg/mL, 120 mL³

| | |
|---|-------------|
| Spirolactone-Hydrochlorothiazide 25 mg/25 mg/tablet | 24 tablets |
| ORA-Blend SF | q.s. 120 mL |

- Expiration 60 days at 5°C and 25°C
- Protect from light
- Shake well before using

RIFAMPIN 25 mg/mL, 120 mL²

| | |
|--------------------------|-------------|
| Rifampin 300 mg/capsules | 10 capsules |
| ORA-Blend SF | q.s. 120 mL |

- Expiration 28 days at 5°C and 25°C
- Protect from light
- Shake well before using

VERAPAMIL HYDROCHLORIDE 50 mg/mL, 120 mL³

| | |
|----------------------------|-------------|
| Verapamil HCl 80 mg/tablet | 75 tablets |
| ORA-Blend SF | q.s. 120 mL |

- Expiration 60 days at 5°C and 25°C
- Protect from light
- Shake well before using

General Directions for Compounding ORA-Blend SF Suspensions

- Calculate the total amount of active ingredient and volume of solution needed to create a suspension of the proper concentration. (Calculations are provided in the examples to the left.) *It may be wise to add approximately 10% overage for compounding losses.*
- Crush tablets with a mortar and pestle to a fine powder. If the compound is already in the powder form, use the mortar and pestle to smooth out the powder.
- Add a small amount of **ORA-Blend SF** and triturate to a thick, smooth paste. Add the remainder of the **ORA-Blend SF** by geometric dilution.
- Mix briefly with a mortar and pestle until a uniform suspension is formed.
- Dispense in a tight, light resistant amber bottle with appropriate labeling.
- Label with an expiration date. *If the stability of the medication in an oral suspension or syrup is unknown, conservative dating is suggested.*
- Depending on the medicinal agent used, label containers “Shake Well Before Using”, “Protect From Light”, and “Keep Refrigerated”.

¹American Journal of Health-System Pharmacists 1999; 56:240-2.

²American Journal of Health-System Pharmacists 1998; 55:1804-9.

³American Journal of Health-System Pharmacists 1996; 53:2179-84.

Contraindications

ORA-Blend SF is contraindicated in persons who have shown hypersensitivity to any of the listed ingredients.

DISCLAIMER:

All information presented is intended to demonstrate the application of Perrigo vehicles in compounding. The information and examples provided in this paper have not been evaluated by the Food and Drug Administration and are provided for educational purposes only. Any information and examples provided are not intended to replace the advice of a physician or take the place of good pharmaceutical compounding practices. The preparation, dispensing, and administration of pharmaceuticals is the responsibility of licensed medical professionals and must adhere to current pharmaceutical compounding requirements and lawful practice of medicine. Perrigo assumes no liability for any injury and/or damage to persons from use of any information and/or examples contained in this document. Perrigo does not warrant against infringements of patents of third parties by reason of any uses made of the vehicles in combination with other material or in the operation of any process. Vehicle purchasers assume all risks of patent infringement by reason of any such use, combination or operation. Before compounding any prescription drug with Perrigo vehicles, please review the full prescribing information of the prescription drug for important safety information and limitations of use.